Next Generation Sequencing Report

January 31, 2014

DUBLIN, January 31, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/zg2p2p/next_generation) has announced the
addition of the “Next Generation Sequencing Report”
[http://www.researchandmarkets.com/research/zg2p2p/next_generation ] report to their

http://photos.prnewswire.com/prnh/20130307/600769 )

NGS technologies drive the way toward personalized medicine

NGS technologies have demonstrated the capacity to sequence DNA at unprecedented
speed, enabling previously unimaginable novel healthcare applications. By providing
valuable data on patient genomes, NGS technologies are filling the gap separating
traditional and personalized medicine. Along with a global shift toward personalized
medicine and through the development of advanced bioinformatic tools, NGS technologies
will have a striking impact on cancer management, treatments of rare diseases and future
developments of genetic therapies.

The change will be gradual, starting with oncology where personalized medicine is more
likely to be accepted. Physicians will have to change their way of working to take full
advantage of this giant leap forward in medicine. To do so, medical school coursework will
likely evolve in the near future to integrate how to work with genomics data.

The Next Generation Sequencing market is poised to reach $4.4B in 2018!

Starting its transition from research to clinical market, the Next Generation
Sequencing (NGS) market will sharply grow from $2.2B to $4.4B in 2018.

That impressive growth will be fueled by huge investments recently made by Diagnostic
companies (Thermo Fisher Scientific, Qiagen, Illumina) associated with the market entry of
new products (PII and PIII, Qiagen’s benchtop, Oxford Nanopore). Previously, the high cost
of both sequencing machines and consumables limited the wide adoption of this technology.
Today, those drawbacks have been resolved with the development of Next Generation
Sequencing Technologies. The attractiveness of the NGS business has caused the number of
suppliers to sharply increase over the last five years. Among them, Illumina is positioned
in first place with around 46% of market share. Thermo Fisher Scientific, in second place,
is the most important challenger.

This analysis provides 2013-2018 market data, along with player market shares at both
equipment and consumable levels. Moreover, positioning strategy of each supplier has been
analyzed in the document. Discover the NGS market’s complex organization, split in four

The market segmentation is a tool used to provide a vision of the market. Based on
technical and economic criteria, fours segments have been identified: research, forensics,
diagnostics and consumer.

Until recently, uses of Next Generation Sequencing tools were limited to research
(human whole genome, exome, small genome, targeted, transcriptome, RNA profiling,
chIP-Seq, metagenomics). Nowadays, NGS technologies have found applications mainly in two
fields: clinical diagnostics and forensics. This investigation describes both current and
future applications.

Key Topics Covered:

1. Executive summary

2. Introduction

3. Market data

4. Market segmentation

5. Next Generation Sequencing technologies overview

6. Value chain and supply chain

7. Market trends and challenges

8. Company profiles

Companies Mentioned:

        - 23andme
        - Affymetrix
        - Azco Biotech Inc
        - Baseclear
        - Base 4
        - BGI-Shenzhen
        - Completegenomics
        - DNAvision
        - Genia Technologies
        - Genapsys
        - GnuBIO
        - Hitachi
        - Illumina
        - LaserGen
        - NabSys
        - Noblegen Biosciences
        - Oxford Nanopore Technologies
        - Pacific Biosciences
        - Qiagen
        - Roche 454
        - Stratos Genomics Inc.
        - Thermo Fisher Scientific
        - TSMC

For more information visit


Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net



SOURCE Research and Markets

Source: PR Newswire

comments powered by Disqus